Patient-Reported Outcomes in Adults with Type 2 Diabetes Using Mealtime Inhaled Technosphere Insulin and Basal Insulin Versus Premixed Insulin

Peyrot, Mark; Rubin, Richard R.

doi:10.1089/dia.2011.0037

Cited by 25 publications

(25 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients were randomized to receive either TI (n = 177), metformin with a secretagogue (n = 162), or a combination of TI with metformin and secretagogue (n = 169). [30] The authors reported an increase in treatment satisfaction after 12 weeks in both the TI arm (p = 0.003) and the TI plus oral therapies arm (p < 0.0001), compared with baseline ratings. These changes were statistically better than those reported in the metformin + secretagogue group (p = 0.0116 for TI alone, p = 0.0009 for TI with oral agents) [30].…”

Section: Used With Permission From Mannkind Corporationmentioning

confidence: 92%

“…Peyrot and colleagues presented data evaluating health-related quality of life (HR-QOL) through the use of the standardized short-form 36 (SF-36) and Insulin Treatment Questionnaire in T2D patients [30]. Patients were randomized to receive either TI (n = 177), metformin with a secretagogue (n = 162), or a combination of TI with metformin and secretagogue (n = 169).…”

Section: Used With Permission From Mannkind Corporationmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Inhaled Insulin in the Management of Type 2 Diabetes

Nuffer¹,

Trujillo²

2016

View full text Add to dashboard Cite

Type 2 diabetes continues to place a major burden on the health care system of the United States and worldwide. Type 2 diabetes involves two major defects: decreased insulin production from the pancreas and increased insulin resistance. Many patients with type 2 diabetes have decreased insulin production which requires exogenous insulin therapy in order to manage their disease. Despite this need, there is often a reluctance to initiate insulin therapy from both providers and patients. One reason for this reluctance may be a fear of needles or of administering injections. Delivering insulin through the lungs has been studied for decades, with the first inhaled insulin product coming to market in 2006. This product's launch was considered unsuccessful, and the product was discontinued by the manufacturer the following year. A new inhaled insulin, Technosphere ® insulin, was approved for use in type 1 and type 2 diabetes in 2014. This product was shown superior to placebo and non-inferior to a premixed bi-phasic subcutaneous insulin in patients with type 2 diabetes, and may offer an alternative to patients who are averse to giving subcutaneous injections.

show abstract

Section: Used With Permission From Mannkind Corporationmentioning

confidence: 92%

Section: Used With Permission From Mannkind Corporationmentioning

confidence: 99%

The Role of Inhaled Insulin in the Management of Type 2 Diabetes

Nuffer¹,

Trujillo²

2016

View full text Add to dashboard Cite

show abstract

“…Phase II Diabetes Peptides [31][32][33][34][35][36][37] Insulin ( microparticles. [8,9] Advanced products include PulmoSphere™ particles, engineered tobramycin-containing hollow porous microparticles made of dipalmitoylphosphatidylcholine (DPPC), the principal component of endogenous lung surfactants.…”

Section: Ave-7279mentioning

confidence: 99%

“…[23] Technosphere™ Insulin (MannKind Corp., Valencia, USA), based on the intermolecular self-assembly of fumaryl diketopiperazine (FDKP), forming a three-dimensional highly porous sphere, is also facing the market. [31,33] Nonetheless, these systems may suffer from the short duration of their therapeutic effect (i.e. frequent administrations).…”

Section: Ave-7279mentioning

confidence: 99%

Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises

Ungaro

d’Angelo

Miro

et al. 2012

Journal of Pharmacy and Pharmacology

160

View full text Add to dashboard Cite

Objectives The aim of this review is to summarize the current state-of-the-art in poly(lactic-co-glycolic acid) (PLGA) carriers for inhalation. It presents the rational of use, the potential and the recent advances in developing PLGA microparticles and nanoparticles for pulmonary delivery. The most promising particle engineering strategies are discussed, highlighting the advantages along with the major challenges for researchers working in this field.

show abstract

“…He was also a participant in the Sensor-Augmented Pump Therapy for A1C Reduction (STAR 2 and STAR 3) trials and collaborated on several articles (e.g., 13). He was involved in planning and research to bring to market an inhaled insulin (AFREZZA), and collaborated on several related articles (e.g., 11,12). He received numerous other grants from companies to conduct research projects on what patients, caretakers, and health care providers wanted and how they were affected by products that companies did or might want to provide.…”

mentioning

confidence: 99%